Last reviewed 2026-05-13 · How we verify

Tedizolid PO

Tedizolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.

Tedizolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Used for Acute bacterial skin and skin structure infections (ABSSSI), Community-acquired bacterial pneumonia (CABP).

At a glance

Mechanism of action

Tedizolid is an oxazolidinone antibiotic that binds to the bacterial 50S ribosomal subunit and inhibits peptidyl transferase, thereby blocking protein synthesis. It is bacteriostatic and has enhanced potency and improved pharmacokinetics compared to linezolid, its parent compound. Tedizolid demonstrates activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and other resistant pathogens.

Approved indications

• Acute bacterial skin and skin structure infections (ABSSSI)
• Community-acquired bacterial pneumonia (CABP)

Common side effects

• Nausea
• Headache
• Diarrhea
• Vomiting
• Peripheral neuropathy
• Optic neuropathy

Key clinical trials

• Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis (PHASE4)
• Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers (PHASE1)
• Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Tedizolid PO CI brief — competitive landscape report
• Tedizolid PO updates RSS · CI watch RSS
• University of Southern California portfolio CI